{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:04:50Z","timestamp":1756339490263,"version":"3.44.0"},"reference-count":22,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,2,26]]},"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:p>We report a case of a 91-year-old Caucasian woman with a history of chronic lymphocytic leukaemia who developed acute hypoxic respiratory failure (AHRF) requiring intubation for less than 24 hours after receiving rasburicase. Laboratory workup was significant for methemoglobinemia and acute anaemia, and blood film demonstrated evidence of oxidative haemolysis with bite cells. The patient was given a presumptive diagnosis of glucose-6-phosphate dehydrogenase (G6PD) deficiency and was managed conservatively with successful resolution of AHRF and stabilisation of haemoglobin level. Seven days after admission, she passed away due to subsequent complications; hence, follow-up G6PD level could not be obtained. Haemolytic anaemia and methemoglobinemia in the setting of recent rasburicase administration should raise clinical suspicion for G6PD deficiency. In non-emergent cases, patients should be screened prior to receiving rasburicase regardless of risk factors. Because rasburicase is often needed emergently, patients at high risk of tumour lysis syndrome should be screened early for G6PD deficiency.<\/jats:p>","DOI":"10.1136\/bcr-2020-240967","type":"journal-article","created":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T13:01:56Z","timestamp":1615899716000},"page":"e240967","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Rasburicase-induced haemolysis and methemoglobinemia: an ongoing issue"],"prefix":"10.1136","volume":"14","author":[{"given":"Luai","family":"Madanat","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, William Beaumont Hospital, Royal Oak, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1396-2765","authenticated-orcid":false,"given":"Daniel","family":"Schoenherr","sequence":"additional","affiliation":[{"name":"Oakland University William Beaumont School of Medicine, Rochester, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Wey","sequence":"additional","affiliation":[{"name":"Department of Pathology, William Beaumont Hospital, Royal Oak, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5637-0674","authenticated-orcid":false,"given":"Ruby","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, William Beaumont Hospital, Royal Oak, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,3,16]]},"reference":[{"key":"2025082707580571000_14.3.e240967.1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200666040-00008"},{"key":"2025082707580571000_14.3.e240967.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.115"},{"key":"2025082707580571000_14.3.e240967.3","unstructured":"Food and Drug Administration . Rasbu- ricase product approval information. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/103946s5083lbl.pdf"},{"key":"2025082707580571000_14.3.e240967.4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.10.2998"},{"key":"2025082707580571000_14.3.e240967.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05094.x"},{"key":"2025082707580571000_14.3.e240967.6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/sj.leu.2403566","article-title":"Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial","volume":"19","author":"Jeha","year":"2005","journal-title":"Leukemia"},{"key":"2025082707580571000_14.3.e240967.7","doi-asserted-by":"publisher","DOI":"10.1177\/1078155211429385"},{"key":"2025082707580571000_14.3.e240967.8","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1600-0609.1968.tb01726.x","article-title":"Sites of destruction of red cells in G-6-PD deficient Caucasians and in phenylhydrazine treated patients","volume":"5","author":"Tizianello","year":"1968","journal-title":"Scand J Haematol"},{"key":"2025082707580571000_14.3.e240967.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60073-2"},{"key":"2025082707580571000_14.3.e240967.10","first-page":"3613","article-title":"Beutler E","volume":"84","year":"1994","journal-title":"G6PD deficiency. Blood"},{"key":"2025082707580571000_14.3.e240967.11","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400850"},{"key":"2025082707580571000_14.3.e240967.12","doi-asserted-by":"publisher","DOI":"10.1080\/10428190600967204"},{"key":"2025082707580571000_14.3.e240967.13","doi-asserted-by":"publisher","DOI":"10.1177\/1060028013501996"},{"key":"2025082707580571000_14.3.e240967.14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/ejh.12350","article-title":"Rasburicase-induced methemoglobinemia in two African-American female patients: an under-recognized and continued problem","volume":"94","author":"Roberts","year":"2015","journal-title":"Eur J Haematol"},{"key":"2025082707580571000_14.3.e240967.15","first-page":"142","article-title":"Rasburicase induced severe hemolysis and methemoglobinemia in a Caucasian patient complicated by acute renal failure and ARDS","volume":"26","author":"Raru","year":"2019","journal-title":"Respir Med Case Rep"},{"key":"2025082707580571000_14.3.e240967.16","doi-asserted-by":"publisher","DOI":"10.1159\/000351048"},{"key":"2025082707580571000_14.3.e240967.17","doi-asserted-by":"publisher","DOI":"10.2174\/1574886312666170111151246"},{"key":"2025082707580571000_14.3.e240967.18","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23182"},{"key":"2025082707580571000_14.3.e240967.19","article-title":"Not the typical pneumonia: an unusual case of Rasburicase-induced Methomoglobinemia","volume":"10","author":"Younis","year":"2018","journal-title":"Cureus"},{"key":"2025082707580571000_14.3.e240967.20","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/MJT.0000000000000028","article-title":"Ascorbic acid for the treatment of methemoglobinemia: the experience of a large tertiary care pediatric hospital","volume":"21","author":"Rino","year":"2014","journal-title":"Am J Ther"},{"key":"2025082707580571000_14.3.e240967.21","doi-asserted-by":"publisher","DOI":"10.1136\/bcr.12.2011.5383"},{"key":"2025082707580571000_14.3.e240967.22","doi-asserted-by":"publisher","DOI":"10.1097\/SMJ.0b013e318232139f"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-240967","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T14:58:13Z","timestamp":1756306693000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-240967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,16]]},"published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1136\/bcr-2020-240967"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-240967","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}